XDXuming Deng

Xuming Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xuming Deng has a total of 201 co-authors. Here are the top co-authors by number of shared publications:

  • Xinxin Ci

    Institute of Zoonoses, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, Jilin, People’s Republic of China

    13 shared publications
  • Xiao Chu

    Institute of Zoonoses, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, Jilin, People’s Republic of China

    10 shared publications
  • Hongyu Li

    Key Laboratory of Zoonosis Research, Institute of Zoonosis, College of Animal Science and Veterinary Medicine, Ministry of Education, Jilin University, Changchun, People’s Republic of China

    6 shared publications
  • Lu Yu

    Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, College of Animal Science and Veterinary Medicine, Jilin University, 5333 Xi'an Road, Changchun, 130062, People's Republic of China

    6 shared publications
  • Dacheng Wang

    Institute of Zoonoses, College of Animal Sciences and Veterinary Medicine, Jilin University, Changchun, China

    5 shared publications
  • Hua Xiang

    Key Laboratory for Protein Sciences of Ministry of Education, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China

    5 shared publications

Latest Publications

  • Open Access

    Concentration of Omega-3 Polyunsaturated Fatty Acids from Rana Egg Oil by Urea Complexation and Response Surface Methodology

    by Dan Li, Mengrou Ren, Jing Lu, Tong Wang, Yixuan Huang, Wei Jiang, Zhang Yan, Yuwen Fang, Xuming Deng, Shuang Guan


  • Nonalcoholic fatty liver disease induced by 13-week oral administration of 1,3-dichloro-2-propanol in C57BL/6J mice

    by Jing Lu, Baochen Fang, Mengrou Ren, Guoren Huang, Shuang Zhang, Yi Wang, Xuming Deng, Shuang Guan


  • Open Access

    Subinhibitory concentrations of pinocembrin exert anti-Staphylococcus aureus activity by reducing α -toxin expression

    by L.W. Soromou, Y. Zhang, Y. Cui, M. Wei, N. Chen, X. Yang, M. Huo, A. Baldé, S. Guan, X. Deng, et al.

    Aims Natural products have been used as potentially important sources of novel antibacterials in combating pathogenic Staphylococcus aureus isolates, a major problem around the world. In this study, we aimed to investigate the antibacterial effects of pinocembrin (PNCB) against Staph. aureus pneumonia in a murine model and its influence on the production of Staph. aureus α‐haemolysin (Hla). Methods and Results The in vitro activities of PNCB on α‐haemolysin production were determined using haemolysis, Western blot and real‐time RT‐PCR assays. The viability and cytotoxicity assays were performed to evaluate the influence of PNCB on α‐toxin‐mediated injury of human alveolar epithelial cells. Moreover, through histopathologic analysis, we further determined the in vivo effects of PNCB on Staph. aureus pneumonia in a mouse model. In vitro, PNCB at low concentrations exhibited inhibitory activity against α‐haemolysin production and attenuated α‐haemolysin‐mediated cell injury. Furthermore, the in vivo findings demonstrated that PNCB protected mice from Staph. aureus pneumonia. Conclusions We have provided new evidence of the effects of PNCB, which suggest that PNCB attenuated α‐haemolysin‐mediated cell injury and protected mice from Staph. aureus pneumonia. Significance and Impact of the Study The findings indicate that PNCB may be used as a basis for anti‐Staphylococcus agent.


  • Open Access

    Erratum to: p-Cymene Modulates In Vitro and In Vivo Cytokine Production by Inhibiting MAPK and NF-κB Activation

    by Weiting Zhong, Gefu Chi, Lanxiang Jiang, Lanan Wassy Soromou, Na Chen, Meixia Huo, Weixiao Guo, Xuming Deng, Haihua Feng


  • p-Cymene Modulates In Vitro and In Vivo Cytokine Production by Inhibiting MAPK and NF-κB Activation

    by Weiting Zhong, Gefu Chi, Lanxiang Jiang, Lanan Wassy Soromou, Na Chen, Meixia Huo, Weixiao Guo, Xuming Deng, Haihua Feng

    The present study was designed to investigate the effects of p-cymene on lipopolysaccharide (LPS)-induced inflammatory cytokine production both in vitro and in vivo. The production of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10) in LPS-stimulated RAW 264.7 cells and C57BL/6 mice was evaluated by sandwich ELISA. Meanwhile, the mRNA levels of cytokine genes were examined in vitro by semiquantitative RT-PCR. In a further study, we analyzed the activation of nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways by western blotting. We found that p-cymene significantly regulated TNF-α, IL-1β, and IL-6 production in LPS-stimulated RAW 264.7 cells. Furthermore, the levels of relative mRNAs were also found to be downregulated. In in vivo trail, p-cymene markedly suppressed the production of TNF-α and IL-1β and increased IL-10 secretion. We also found that p-cymene inhibited LPS-induced activation of extracellular signal receptor-activated kinase 1/2, p38, c-Jun N-terminal kinase, and IκBα. These results suggest that p-cymene may have a potential anti-inflammatory action on cytokine production by blocking NF-κB and MAPK signaling pathways.


  • Open Access

    Crystal Structures Reveal the Multi-Ligand Binding Mechanism of Staphylococcus aureus ClfB

    by Hua Xiang, Yue Feng, Jiawei Wang, Bao Liu, Yeguang Chen, Lei Liu, Xuming Deng, Maojun Yang

    Staphylococcus aureus (S. aureus) pathogenesis is a complex process involving a diverse array of extracellular and cell wall components. ClfB, an MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) family surface protein, described as a fibrinogen-binding clumping factor, is a key determinant of S. aureus nasal colonization, but the molecular basis for ClfB-ligand recognition remains unknown. In this study, we solved the crystal structures of apo-ClfB and its complexes with fibrinogen α (Fg α) and cytokeratin 10 (CK10) peptides. Structural comparison revealed a conserved glycine-serine-rich (GSR) ClfB binding motif (GSSGXGXXG) within the ligands, which was also found in other human proteins such as Engrailed protein, TCF20 and Dermokine proteins. Interaction between Dermokine and ClfB was confirmed by subsequent binding assays. The crystal structure of ClfB complexed with a 15-residue peptide derived from Dermokine revealed the same peptide binding mode of ClfB as identified in the crystal structures of ClfB-Fg α and ClfB-CK10. The results presented here highlight the multi-ligand binding property of ClfB, which is very distinct from other characterized MSCRAMMs to-date. The adherence of multiple peptides carrying the GSR motif into the same pocket in ClfB is reminiscent of MHC molecules. Our results provide a template for the identification of other molecules targeted by S. aureus during its colonization and infection. We propose that other MSCRAMMs like ClfA and SdrG also possess multi-ligand binding properties. Staphylococcus aureus (S. aureus), an important opportunistic pathogen, is a major threat to humans and animals, causing high morbidity and mortality worldwide. It is responsible for a variety of infections ranging from mild superficial infections to severe infections such as infective endocarditis, septic arthritis, osteomyelitis and sepsis. Such infections are of growing concern due to the increasing antibiotic resistance of S. aureus. In order to understand the mechanism of the S. aureus pathogenesis, we studied one of the bacterial surface proteins clumping factor B (ClfB) bound by the fibrinogen α (Fg α) and cytokeratin 10 (CK10). From analyses of the high resolution crystal structures we found that the ClfB-binding peptides harbor a stretch with consensus sequence (GSSGXGXXG) that is also conserved in Engrailed protein, TCF20 and Dermokines. The interaction between ClfB and a dermokine-derived peptide was demonstrated using binding assays. Consistent with a role of ClfB in the inflammatory responses induced by S. aureus, expression of dermokines is predominant in epithelial tissues and upregulated in inflammatory diseases. The data presented in this study raise a possibility that multiple human proteins are targeted by ClfB during S. aureus infection. The multi-ligand binding feature of ClfB would be valuable for developing new therapeutic strategies.


  • Open Access

    Different Effects of Farrerol on an OVA-Induced Allergic Asthma and LPS-induced Acute Lung Injury

    by Xinxin Ci, Xiao Chu, Miaomiao Wei, Xiaofeng Yang, Qinren Cai, Xuming Deng

    Farrerol, isolated from rhododendron, has been shown to have the anti-bacterial activity, but no details on the anti-inflammatory activity. We further evaluated the effects of this compound in two experimental models of lung diseases. For the asthma model, female BALB/c mice were challenged with ovalbumin (OVA), and then treated daily with farrerol (20 and 40 mg/kg, ip) as a therapeutic treatment from day 22 to day 26 post immunization. To induce acute lung injury, female BALB/c mice were injected intranasally with LPS and treated with farrerol (20 and 40 mg/kg, i.p.) 1 h prior to LPS stimulation. Inflammation in the two different models was determined using ELISA, histology, real-time PCR and western blot. Farrerol significantly regulated the phenotype challenged by OVA, like cell number, Th1 and Th2 cytokines levels in the BALF, the OVA-specific IgE level in the serum, goblet cell hyperplasia in the airway, airway hyperresponsiveness to inhaled methacholine and mRNA expression of chemokines and their receptors. Furthermore, farrerol markedly attenuated the activation of phosphorylation of Akt and nuclear factor-κB (NF-κB) subunit p65 both in vivo and in vitro. However, farrerol has no effect on the acute lung injury model. Our finding demonstrates that the distinct anti-inflammatory effect of farrerol in the treatment of asthma acts by inhibiting the PI3K and NF-κB pathway.


  • Short-term roxithromycin treatment attenuates airway inflammation via MAPK/NF-κB activation in a mouse model of allergic asthma

    by Xinxin Ci, Xiao Chu, Xue Xu, Hongyu Li, Xuming Deng

    Objective We investigated whether roxithromycin reduces ovalbumin-specific allergic asthma symptoms in mice, and we further investigated the inhibitory mechanism of roxithromycin in ovalbumin-specific allergic asthma. Methods Mice were divided into five groups (n = 10 for each): control group, roxithromycin-treated groups (5, 20 and 40 mg/kg) and ovalbumin-challenged group. We measured the recruitment of inflammatory cells into the bronchoalveolar lavage fluid (BALF) or the lung tissues by Kwik-Diff and hematoxylin and eosin (H&E) staining, goblet cell hyperplasia by alcian blue–periodic acid–Schiff (AB-PAS) staining, airway hyperresponsiveness (AHR) by whole-body plethysmograph chamber, cytokine and immunoglobulin E (IgE) levels by ELISA, and the activation of mitogen-activated protein (MAP) kinases and nuclear factor-kappa B (NF-κB) in the lung tissues by Western blotting. Results Treatment with roxithromycin resulted in fewer inflammatory cells in the BALF and peribronchial areas, and decreased AHR, goblet cell hyperplasia, IgE levels and inflammatory cytokines, as well as MAP kinases and NF-κB activation, which are increased in lung tissues of mice with ovalbumin-induced allergic asthma. Conclusions Our data suggest that oral administration of roxithromycin suppresses ovalbumin-induced airway inflammation and AHR by regulating the inflammatory cytokines via MAP kinases/NF-κB pathway in inflammatory cells. Based on these results, we suggest that roxithromycin may be used as a therapeutic agent for allergy-induced asthma.


  • Licochalcone A Inhibits Lipopolysaccharide-Induced Inflammatory Response in Vitro and in Vivo

    by Xiao Chu, Xinxin Ci, Miaomiao Wei, Xiaofeng Yang, Qingjun Cao, Mingfeng Guan, Hongyu Li, Yanhong Deng, Haihua Feng, Xuming Deng

    Licochalcone A (Lico A), a flavonoid found in licorice root (Glycyrrhiza glabra), is known for its antimicrobial activity and its reported ability to inhibit cancer cell proliferation. In the present study, we found that Lico A exerted potent anti-inflammatory effects in in vitro and in vivo models induced by lipopolysaccharide (LPS). The concentrations of TNF-α, interleukin (IL)-6, and IL-1β in the culture supernatants of RAW 264.7 cells were determined at different time points following LPS administration. LPS (0.5 mg/kg) was instilled intranasally (i.n.) in phosphate-buffered saline to induce acute lung injury, and 24 h after LPS was given, bronchoalveolar lavage fluid was obtained to measure pro-inflammatory mediator and total cell counts. The phosphorylation of mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB) p65 protein was analyzed by Western blotting. Our results showed that Lico A significantly reduced the amount of inflammatory cells, the lung wet-to-dry weight (W/D) ratio, protein leakage, and myeloperoxidase activity and enhances oxidase dimutase activity in mice with LPS-induced acute lung injury (ALI). Enzyme-linked immunosorbent assay results indicated that Lico A can significantly down-regulate TNF-α, IL-6, and IL-1β levels in vitro and in vivo, and treatment with Lico A significantly attenuated alveolar wall thickening, alveolar hemorrhage, interstitial edema, and inflammatory cells infiltration in mice with ALI. In addition, we further demonstrated that Lico A exerts an anti-inflammation effect in an in vivo model of acute lung injury through suppression of NF-κB activation and p38/ERK MAPK signaling in a dose-dependent manner.


  • Protocatechuic Acid Attenuates Lipolysaccharide-Induced Acute Lung Injury

    by Miaomiao Wei, Xiao Chu, Lanxiang Jiang, Xiaofeng Yang, Qinren Cai, Chaochao Zheng, Xinxin Ci, Mingfeng Guan, Juxiang Liu, Xuming Deng

    Protocatechuic acid (PCA) is a major metabolite of anthocyanins. It has numerous pharmacological effects, including anti-inflammatory, antioxidant, and antitumoral activities. In the present study, we investigated the in vivo protective effect of PCA on acute lung injury (ALI) induced by lipolysaccharide (LPS) in mice. We treated mice with PCA 1 h before the intratracheal (i.n.) administration of LPS. The pulmonary injury severity was evaluated 6 h after LPS administration. We found that pretreatment with a 30 mg/kg of PCA markedly attenuated the LPS-induced histological alterations in the lung. In addition, PCA inhibited the production of several inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and IL-6, at 6 h in the bronchoalveolar lavage fluid (BALF) after LPS challenge. Furthermore, PCA significantly reduced the number of total cells, neutrophils, and macrophages in the BALF, and it significantly decreased the wet/dry weight (W/D) ratio of lungs and the protein concentration in the BALF. Additionally, Western blotting showed that PCA efficiently blunted nuclear factor-kappa B (NF-κB) activation by inhibiting the degradation and phosphorylation of IκBα, as well as the translocation of p65 from cytoplasm to the nucleus. In conclusion, these results indicate that PCA was highly effective in inhibiting acute lung injury (ALI) and may be a promising potential therapeutic reagent for ALI treatment. PCA may utilize the NF-κB pathway to attenuate the nonspecific pulmonary inflammation induced by LPS administration.